Overview
- The company announced the $150 million Series C led by Bain Capital Ventures on Sept. 8, 2026 with existing backers such as Thrive Capital, General Catalyst and Accel also participating.
- Forus builds autonomous AI agents that act like automated case managers to handle prior authorizations, financial assistance and specialty pharmacy routing for prescribed therapies.
- The startup says its platform is free to providers and patients and that it monetizes through partnerships with biopharma firms, including nine of the world’s 15 largest drug companies.
- Forus reports a national footprint across all 50 states reaching about 85% of U.S. residential ZIP codes and cites specialty adoption metrics such as strong early uptake in rheumatology, though these figures come from the company.
- The company says it will use the proceeds to add more specialties, expand technology and hire staff while claiming its agents cut prior-authorization times to under 48 hours and speed therapy starts to one to two weeks, claims that have not been independently verified.